Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study.
- DOI
- 10.1002/cam4.3091
- Published
- 2020 Jul
- Container
- Cancer medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/cam4.3091,
title = {Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study.},
author = {Takahashi M and Masuda N and Nishimura R and Inoue K and Ohno S and Iwata H and Hashigaki S and Muramatsu Y and Umeyama Y and Toi M},
year = {2020},
journal = {Cancer medicine},
doi = {10.1002/cam4.3091},
url = {https://doi.org/10.1002/cam4.3091}
}RIS
TY - JOUR TI - Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study. AU - Takahashi M AU - Masuda N AU - Nishimura R AU - Inoue K AU - Ohno S AU - Iwata H AU - Hashigaki S AU - Muramatsu Y AU - Umeyama Y AU - Toi M PY - 2020 JO - Cancer medicine DO - 10.1002/cam4.3091 UR - https://doi.org/10.1002/cam4.3091 ER -
APA
M, T., N, M., R, N., K, I., S, O., H, I., S, H., Y, M., Y, U., & M, T. (2020). Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study.. Cancer medicine. https://doi.org/10.1002/cam4.3091
Source records
- pubmed · retrieved 2026-09-26T16:50:49.733Z